New Amsterdam Pharma opened higher at $20.76, compared with its previous close of $20.72. In the last trading session, the stock traded between $19.31 and $20.76. It showed a downward intraday trend.
An investment of $100 made 4 years ago in New Amsterdam Pharma is now worth
$ 193.14
Giving a profit of
$ 93.14 (93.14%)
Note: Past profits do not guarantee future returns.
Rating from 10 Analysts
Today's Change
$-0.73 (-3.52%)
Day High
$20.76
Day Low
$19.31
Day Open
$20.76
Prev Close
$20.72
Volume
20,64,861
1W Return
-4.31%
1M Return
-5.92%
3M Return
-27.62%
6M Return
-49.51%
1Y Return
-49.89%
Market Cap ($ Mn)
2,397
PE Ratio
-
PB Ratio
4.83
PEG Ratio
-
ROE
-27.36%
ROCE
-31.06%
EPS (TTM)
-
1 Week
-4.31%
1 Month
-5.92%
3 Months
-27.62%
6 Months
-49.51%
9 Months
-41.62%
Cantor Fitzgerald raises NewAmsterdam Pharma price target to $61
Cantor Fitzgerald raised the price target for NewAmsterdam Pharma Co to $61. The previous price target was set at $52. Analyst Steve Seedhouse maintained an Overweight rating on the stock.
YesterdayNewAmsterdam Pharma grants inducement shares to six new hires
Granted 106,600 share options to six non-executive new hires. Exercise price set at $19.56 per share, matching Nov 2 closing price. Additional 28,295 restricted stock units granted to the same group. Options vest over four years; RSUs vest over three years.
6 days agoNewAmsterdam Pharma grants inducement shares to new hires
NewAmsterdam Pharma granted options on 71,800 shares and RSUs on 17,745 shares to seven new hires. Share options have an exercise price of $24.16, matching the closing market price on October 1, 2026. Options vest over four years with a 25% cliff, while RSUs vest over three years in annual tranches. Grants were made under the 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
1mo agoNewAmsterdam Pharma secures first global EU approval for obicetrapib
European Commission grants first global marketing approval for obicetrapib therapies Ubeslo and Evlarco. Phase 3 trials showed up to 40% LDL-C reduction with monotherapy and 50% with fixed-dose combination. Menarini Group holds exclusive European commercialization rights with potential €833 million in milestones. Approval addresses unmet need for patients requiring oral non-statin therapies for elevated LDL-C.
1mo agoNewAmsterdam Pharma to participate in two investor conferences in September
NewAmsterdam Pharma will participate in two investor conferences in September 2026. The Wells Fargo 21st Annual Healthcare Conference is scheduled for September 9, 2026 in Boston, MA, featuring a fireside chat at 3:45 pm ET. The Cantor Global Healthcare Conference 2026 is scheduled for September 10, 2026 in New York, NY, featuring a fireside chat at 2:45 pm ET. Live webcasts and archived replays of both presentations will be available on the company's investor relations website. NewAmsterdam Pharma is developing obicetrapib, an oral once-daily CETP inhibitor, for patients at risk of cardiovascular disease with elevated LDL-C.
2mo agoNewAmsterdam Pharma grants 28,000 inducement options at $27.79
NewAmsterdam Pharma Company N.V. granted 28,000 share options at $27.79 and 8,200 RSUs to three new non-executive employees. The awards vest over three to four years and comply with Nasdaq Listing Rule 5635(c)(4).
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 4 years ago in New Amsterdam Pharma is now worth
$ 193.14
Giving a profit of
$ 93.14 (93.14%)
Note: Past profits do not guarantee future returns.
